Close

Biolase (BIOL) PT Raised to $3 at Ascendiant Capital as Turnaround Takes Hold

August 19, 2021 6:46 AM EDT Send to a Friend
Ascendiant Capital analyst Edward Woo raised the price target on Biolase (NASDAQ: BIOL) to $3.00 (from $2.00) after Total revenue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login